Table 6 Characteristics of patients with severe asthma exacerbations
CVT-MDI | ALB-HFA | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Patient 10868 | Patient 11356 | Patient 11473 | Patient 12410 | Patient 12454 | Patient 10853 | Patient 11752 | Patient 11803 | Patient 12055 | |
Age (years), gender, race | 52, Female, Caucasian | 69, Female, Caucasian | 64, Female, Hawaiian/PI | 36, Female, Caucasian | 59, Male, Caucasian | 45, Female, Afr Amer | 35, Male, Afr Amer | 49, Female, Caucasian | 74, Female, Caucasian |
BMI (kg/m2) | 33.2 | 32.5 | 22.5 | 48.2 | 28.6 | 41.4 | N/A | N/A | 29.0 |
Exacerbation - start day, phase | Day 3, Ph 1 | Day 2, Ph 1 | Day 29, Ph 1 | Day 24, Ph 1 | Day 15, Ph 1 | Day 19, Ph 2 | Day 29, Ph 2 | Day 11, Ph 2 | Day 22, Ph 2 |
Exacerbation in prior year | None | Yes, 2 months prior | None | Yes, 6 months prior | Yes, 2.5 months prior | None | N/A | Yes, 6 months prior | None |
Baseline FEV1 % predicted | 56.3 % | 36.4 % | 41.4 % | 71.3 % | 64.9 % | 52.3 % | 46.8 % | 63.7 % | 72.5 % |
Background and concomitant asthma medications (daily dose) | Advair 500/100 μg; Alb 180 μg, d/c; | Symbicort 640/18 μg; | Advair 1000/100 μg; Alb 180 μg, d/c; | Advair 250/50 μg; Singulair 10 mg; Zyrtec; Flonase; | Advair 1000/100 μg; Singulair 10 mg; | Advair 1000/100 μg | Advair 1000/100 μg; Singulair 10 mg; Alb 180 μg, d/c; Zyrtec D; Nasonex; | Flovent 440 μg, Combivent 84/480 μg, Alb 180 μg, d/c Flonase | Xopenex 2.5 mg, Pulmicort 360 μg, Alb, d/c |
Respiratory infection reported preceding exacerbation | No | No | No | No | No | Yes | Yes | No | No |
Use of rescue medication (No. of puffs) 3 days before and day of exacerbation | −3 days: 2 | −3 days: 2 | −3 days: 4 | −3 days: 0 | −3 days: 5 | −3 days: 2 | −3 days: 6 | −3 days: 6 | −3 days: 4 |
−2 days: 4 | −2 days: 3 | −2 days: 8 | −2 days: 2 | −2 days: 4 | −2 days: 0 | −2 days: 8 | −2 days:6 | −2 days: 4 | |
−1 day: 2 | −1 day: 3 | −1 day: 4 | −1 day: 2 | −1 day: 5 | −1 day: 6 | −1 day: 6 | −1 day: 6 | −1 day: 4 | |
0: 4 | 0: 6 | 0: 0 | 0: 2 | 0: 7 | 0: 4 | 0: N/A | 0: 6 | 0: 6 | |
PEF (L/min) 3 days before and day of exacerbation (best of day) | −3 days: 365 | −3 days: 189 | −3 days: 155 | −3 days: 381 | −3 dy: 371 | −3 days: 254 | −3 days: 388 | −3 days: 392 | −3 days: 339 |
−2 days: 359 | −2 days: 160 | −2 days: 172 | −2 dy: 392 | −2 days: 399 | −2 days: 227 | −2 days: 298 | −2 days: 395 | −2 days: 334 | |
−1 day: 353 | −1 day: 180 | −1 day: 129 | −1 day: 426 | −1 day: 337 | −1 day: 180 | −1 day: 307 | −1 day: 406 | −1 day: 305 | |
0: 350 | 0: 181 | 0: 104 | 0: 368 | 0: 353 | 0: 194 | 0: 284 | 0: 374 | 0: 281 | |
Duration of exacerbation | 17 days | 9 days | 4 days | 9 days | 7 days | 9 days | 13 days | 81 days | 11 days |
PEF (L/min) 3 days after end of exacerbation | +1 day: 356 | +1 day: 154 | N/A | +1 day: 368 | +1 day: 492 | +1 day: 310 | N/A | +1 day: 326 | N/A |
+2 days: 311 | +2 days: 155 | +2 days: 402 | +2 days: 486 | +2 days: 347 | +2 days: 344 | ||||
+3 days: 361 | +3 days: 153 | +3 days: 384 | +3 days: 536 | +3 days: 271 | +3 days: 314 | ||||